Libtayo (cemiplimab), approved as treatment for advanced cases of squamous cell carcinoma of the skin, might soon have a role in the treatment of local cases of the disease.

Results of a phase 3 trial reported today at the American Society of Clinical Oncology meeting showed a significant benefit from Libtayo when it was given to patients with localized squamous cell carcinoma after the cancer had been treated with surgery and radiation. In addition to this “adjuvant” use of Libtayo, other research has suggested that the cancer drug may benefit patients as a “neoadjuvant” treatment that is given before surgery and radiation.

The findings presented today were limited to patients with local squamous cell carcinoma that had characteristics that suggest a higher-than-normal risk of recurrenc

See Full Page